Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) generates news at the intersection of cell therapy, oncology and metabolic disease research. Company announcements and SEC-referenced disclosures describe a business that has combined T-cell receptor (TCR) cell therapy programs for solid tumors with a preclinical-stage obesity and metabolic health drug development effort built around a small molecule candidate.
News items for TCRT commonly cover clinical and translational updates from its TCR-T Library Phase 1/2 trial at The University of Texas MD Anderson Cancer Center, including disease control rates, objective responses in metastatic, refractory solid tumors, and safety and tolerability findings for its Sleeping Beauty-engineered TCR-T cells. Releases also highlight the capabilities of the hunTR ae TCR discovery platform, which the company reports has identified proprietary TCRs targeting driver mutations such as KRAS and TP53.
Investors following TCRT news will also see coverage of Alaunos strategic reprioritization and corporate actions. The company has publicly discussed winding down its TCR-T clinical trial, refocusing on the hunTR ae platform, and exploring strategic alternatives that may include acquisitions, mergers, reverse mergers, asset sales, partnerships or capital raises. Financial results releases detail research and development spending, restructuring costs, workforce reductions and cash runway expectations as the company adjusts its operations.
In addition, Alaunos issues news on capital markets activity, such as registered direct offerings of common stock and pre-funded warrants under a shelf registration statement, private offerings of convertible preferred stock, and equity purchase agreements registered on Form S-1. Governance and listing-related updates, including board changes, executive transitions and Nasdaq compliance notices and resolutions, also appear in the news flow. For readers tracking TCRT, this page aggregates these operational, clinical, financial and regulatory developments in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Alaunos Therapeutics, Inc. (TCRT), a leader in T-cell receptor (TCR) cell therapy, announced a poster presentation for its lead Sleeping Beauty TCR-T cell therapy program at the 2023 ASCO Annual Meeting from June 2-6, 2023, in Chicago. The TCR-T Library Phase 1/2 trial is an open-label, dose-escalation study conducted at MD Anderson Cancer Center, focusing on patients with solid tumors, including non-small cell lung and colorectal cancers, who have specific targeted driver mutations. The poster will detail the safety and efficacy of TCR-T cells targeting shared KRAS and TP53 mutations. The presentation is scheduled for June 3, 2023, showcasing Alaunos' advancements in TCR therapy for cancer treatment.
Alaunos Therapeutics (Nasdaq: TCRT) announced the appointment of Robert J. Hofmeister, PhD, as Chief Scientific Officer of the Board of Directors, effective immediately. Hofmeister replaces Chris Bowden, MD. With over 25 years of expertise in T-cell therapy, Hofmeister previously led scientific teams at TCR2 Therapeutics and played a crucial role in developing their TRuC®-T cell platform. Alaunos aims to advance its TCR-T Library Phase 1/2 trial targeting solid tumors. The company benefits from its proprietary Sleeping Beauty cell engineering platform and industry-leading library of TCRs. The ongoing collaboration with the National Cancer Institute supports its research and development efforts.
Alaunos Therapeutics (Nasdaq: TCRT), a prominent T-cell receptor cell therapy company, announced its participation in two upcoming investor conferences. The first is Cantor's The Future of Oncology Virtual Symposium on April 4, 2023, featuring fireside chats and one-on-one meetings. The second is the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, which will include a company presentation and one-on-one meetings. A live webcast of the Needham presentation will be available on Alaunos' website for 90 days post-event. Alaunos is advancing TCR therapies for solid tumors and collaborates with the National Cancer Institute.
FAQ
What is the current stock price of Alaunos Therapeutics (TCRT)?
What is the market cap of Alaunos Therapeutics (TCRT)?
